Skip to content

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07312474
Acronym
ANARETRO
Enrollment
100
Registered
2025-12-31
Start date
2024-10-02
Completion date
2026-02-28
Last updated
2025-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Anaplasmosis

Keywords

Human Anaplasmosis, Ticks, Tick bite, Severe cytopenias, Respiratory distress syndrome, Septic shock, Neurological disorders, Macrophage activation syndrome

Brief summary

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult subjct (≥18 years) * Presenting with a PCR-confirmed infection of Anaplasma

Exclusion criteria

\- Refusal to participate in the study

Design outcomes

Primary

MeasureTime frame
Mortality of cases of human anaplasmosis in AlsaceUp to 12 years

Countries

France

Contacts

Primary ContactVictor GERBER, MD
victor.gerber@chru-strasbourg.fr33 3.88.11.67.68

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026